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Evaluation of the Efficacy and Safety of High Dose Short Duration
Enrofloxacin Treatment Regimen for Uncomplicated Urinary Tract
Infections in Dogs
J.L. Westropp, J.E. Sykes, S. Irom, J.B. Daniels, A. Smith, D. Keil, T. Settje, Y. Wang, and D.J. Chew
Background: Uncomplicated urinary tract infections (UTI) in dogs usually are treated with antimicrobial drugs for
10–14 days. Shorter duration antimicrobial regimens have been evaluated in human patients.
Hypothesis: A high dose short duration (HDSD) enrofloxacin protocol administered to dogs with uncomplicated UTI
will not be inferior to a 14-day treatment regimen with amoxicillin-clavulanic acid.
Animals: Client-owned adult, otherwise healthy dogs with aerobic bacterial urine culture yielding  103 CFU/mL of
bacteria after cystocentesis.
Methods: Prospective, multicenter, controlled, randomized blinded clinical trial. Enrolled dogs were randomized to
group 1 (enrofloxacin 18–20 mg/kg PO q24h for 3 days) or group 2 (amoxicillin-clavulanic acid 13.75–25 mg/kg PO q12h
for 14 days). Urine cultures were obtained at days 0, 10, and 21. Microbiologic and clinical cure rates were evaluated
7 days after antimicrobial treatment was discontinued. Lower urinary tract signs and adverse events also were recorded.
Results: There were 35 dogs in group 1 and 33 in group 2. The microbiologic cure rate was 77.1 and 81.2% for groups
1 and 2, respectively. The clinical cure rate was 88.6 and 87.9% for groups 1 and 2, respectively. Cure rates between
groups did not differ according to the selected margin of noninferiority.
Conclusions and Clinical Importance: HDSD enrofloxacin treatment was not inferior to a conventional amoxicillin-
clavulanic acid protocol for the treatment of uncomplicated bacterial UTI in dogs. Further research is warranted to deter-
mine if this protocol will positively impact owner compliance and decrease the emergence of antimicrobial resistance.
Key words: Amoxicillin-clavulanic acid; Bladder; Enrofloxacin; Lower urinary tract infection.
Bacterial urinary tract infections (UTIs) have beenestimated to occur in approximately 14% of dogs
during their lifetime,1 with a variable age of onset. The
clinical signs of bacterial cystitis include stranguria,
pollakiuria, inappropriate urinations, dysuria, and
hematuria. Clinically occult UTIs in dogs and cats also
have been reported.2,3 Although there are no studies in
dogs to determine the appropriate duration of treat-
ment for simple, uncomplicated UTIs, they usually are
treated for 7–14 days.4–6 Uncomplicated UTI is
defined as a UTI without structural, metabolic, or
functional urinary tract abnormalities, as well as the
absence of other comorbidities, such as cystic calculi,
bladder neoplasia, and systemic disorders, such as
uncontrolled diabetes mellitus or hyperadrenocortic-
ism7 that could favor a more serious adverse outcome.
A longer duration of treatment has been suggested for
humans8 and dogs6 with complicated UTIs.
In human patients, uncomplicated UTIs often are trea-
ted for a maximum of 3 days; however, single dose proto-
cols also have been described.9,10 Various antimicrobial
regimens for UTI, including fluoroquinolones, have been
evaluated; relapsing infections were reported more often
in single dose protocols.10–12 A relapsing or persistent
infection occurs when the initial infection was not
resolved despite treatment. In contrast, reinfections also
may occur, but imply that a new bacterial species or
strain infects the patient after a period of sterility.13 Effi-
cacy of short duration treatment regimens has been vari-
able, but some higher dose protocols appear to result in
longer short- and long-term cure rates.14 Fluoroquinol-
ones are commonly used15,16 because of their spectrum of
activity against uropathogens and the high concentra-
tions that are achieved in urine.17,18 In humans, short
durations of treatment and decreased dosing frequency
of antimicrobials have been reported to increase compli-
ance, lower costs, decrease adverse effects, and may be as
effective as conventional protocols.7,19
Fluoroquinolones also have been used to treat UTI in
dogs. Enrofloxacina is a fluoroquinolone antimicrobial
drug that was developed specifically for veterinary use,
and approved dosages range from 5 to 20 mg/kg PO
q24h. The efficacy of a high dose, short duration
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(HDSD) antimicrobial regimen in naturally occurring
UTI in dogs has not been evaluated. Therefore, the pur-
pose of this study was to evaluate the efficacy of a 3-day
course of HDSD enrofloxacin compared with a 14-day
period of treatment with amoxicillin-clavulanic acidb for
uncomplicated UTI in dogs. Amoxicillin-clavulanic acid
was chosen because this antibiotic is approved for treat-
ment of UTI in dogs, has a spectrum of activity against
common uropathogens, reaches high concentrations in
the urine, and is commonly prescribed by primary care
veterinarians.4,20 We hypothesized that in naturally occur-
ring uncomplicated UTI, neither microbiologic cure rate
nor clinical resolution rate would be significantly dif-
ferent between the 2 treatment groups.
Materials and Methods
Study Design
This was a prospective, multicenter, controlled, randomized,
and blinded clinical trial. The trial was conducted in accordance
with Guidance for Industry #85, Good Clinical Practice.c The
study was performed at 2 university teaching hospitals (William
R. Pritchard, Veterinary Medical Teaching Hospital at University
of California, Davis, and The Ohio State University Veterinary
Medical Center) as well as 3 veterinary private practice sites
located in Missouri, Louisiana, and Pennsylvania.
Client-owned, adult dogs that weighed 5–50 kg and that were
suspected to have an uncomplicated clinical UTI at each study
site were eligible for enrollment. Juvenile dogs were excluded
from the study because articular cartilage lesions have been
reported with the use of fluoroquinolones in rapidly growing
dogs.21 Young age was defined as <9 months of age for dogs that
weighed 5.0–25.9 kg at maturity, <1 year for dogs that weighed
26–45 kg, and <18 months for dogs that weighed >45 kg. A com-
plete medical history was collected. Dogs were excluded from the
study if they had a history of persistent or recurrent UTI (defined
as >3 UTIs in 1 year with or without a period of sterility), or
uncontrolled systemic comorbid diseases that could predispose
the dog to recurrent infections. Dogs with diabetes mellitus,
hyperadrenocortocism, and urinary incontinence also were
excluded. Antimicrobial drug administration within 7 days or
corticosteroid administration within 14 days of initial presenta-
tion or other compounds containing metal cations or administra-
tion of antacids also were criteria for exclusion, the latter
because these cations can bind to enrofloxacin and decrease its
absorption.20
On day 0, a physical examination, which included bladder pal-
pation, was performed on all dogs by 1 of the study investiga-
tors. The presence or absence of lower urinary tract signs
(LUTS) was recorded. LUTS were defined as pollakiuria, strang-
uria, and hematuria. A complete blood count (CBC) and serum
biochemical analysis also were performed on day 0. In addition,
urine was collected by cystocentesis and subjected to urinalysis
and quantitative aerobic bacterial urine culture with susceptibility
testing by broth microdilution using minimum inhibitory concen-
tration (MIC) testing.
To be enrolled in the study, dogs had to be deemed otherwise
healthy based on the history, physical examination, and absence
of abnormalities on the CBC and serum biochemical analysis.
Ultrasound examination of the urinary bladder was performed
only in dogs seen at the university sites. Only dogs with aerobic
bacterial urine cultures that yielded  103 CFU/mL of at least 1
of the isolates or a mixture of up to 2 target pathogenic bacteria
were definitively eligible for inclusion. Pathogenic bacteria were
defined as Escherichia coli, Proteus spp., Klebsiella spp., Pseudo-
monas aeruginosa, Enterobacter spp., Staphylococcus aureus,
Staphylococcus intermedius group (S. pseudintermedius, S. inter-
medius, S. delphini), alpha-hemolytic Streptococcus spp., and
Enterococcus spp. Dogs were included if nontargeted bacteria
were isolated in conjunction with the targeted pathogens. Dogs
with suspected or confirmed pyelonephritis, prostatitis, urinary
tract neoplasia, urinary calculi, uncontrolled systemic disease,
spinal cord injuries, and suspected CNS disorders were not
eligible for enrollment.
Enrolled dogs then were randomized to group 1 or group 2 by
random number generation to ensure an equal number of dogs in
each group. Dogs in group 1 received enrofloxacin,a 18–20 mg/kg
PO q24h for 3 days. Dogs in group 2 received amoxicillin-clavul-
anic acid,b 13.75–25 mg/kg PO q12h for 14 days. An unblinded
veterinary technician enrolled dogs and dispensed medications
for each study site. The time of day the antimicrobial was to be
administered was not specified to the client. The technician
instructed all pet owners not to discuss the treatment regimen
with anyone other than the dispenser, but did not otherwise par-
ticipate in the clinical observations. All veterinarians who per-
formed clinical observations were blinded to treatment group.
During the study period, dog owners were asked to record con-
comitant medications and adverse events that occurred. They
were instructed to return their dog to the study site on day 10
(±2 days) and day 21 (±2 days) and bring the prescribed antimi-
crobial drug with them. During these visits, a complete history
was obtained, pills were counted, and a physical examination,
urinalysis, and quantitative aerobic bacterial urine culture and
susceptibility testing were performed.
Microbiologic cure and clinical cure were evaluated as study
endpoints 7 days after discontinuation of antimicrobial treat-
ment, which corresponded to day 10 for group 1 and day 21 for
group 2. Long-term microbiologic and clinical cure rates also
were determined for group 1 dogs on day 21, 18 days after com-
pleting enrofloxacin treatment. Only dogs that had urine cultures
performed at those times points were included in the statistical
analysis for microbiologic cure. If an animal was removed
because of persistent clinical signs, it was considered a clinical
failure. Microbiologic cure was defined as a negative aerobic
bacterial urine culture, or a culture that yielded <103 CFU/mL of
bacteria. Microbiologic failure was defined as an aerobic bacterial
urine culture that yielded >103 CFU/mL of the same pathogen as
detected in the pretreatment urine specimen. Clinical cure was
defined as a lack of any LUTS.
Culture and Susceptibility Testing
Urine cultures and antimicrobial susceptibility testing were
performed at the hospital microbiology laboratories (university
sites) or at an independent laboratoryd for the private practice
sites. Culture and susceptibility testing procedures were per-
formed in a similar manner at each laboratory. Quantitative
urine cultures were performed by streaking 5% defibrinated
sheep blood and MacConkey agarse each with 10 lL of urine
using a calibrated loop. Plates were incubated at 35°C in 5%
CO2 or ambient air. Organisms were identified using routine
microbiologic biochemical testing, including gram stain, spot test-
ing (indole, oxidase), tubed biochemical media, and bacterial
identification kits.f,22 Cultures were considered negative when
there was no growth after 3 days. Susceptibility testing was per-
formed by broth microdilution according to Clinical Laboratory
Standards Institute (CLSI) methods using a commercially avail-
able panel of antimicrobial drugs.g,23 Interpretive breakpoints
were based on CLSI standards for small animals when available,
otherwise standards for human patient isolates were used.24
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Statistical Analysis
Noninferiority tests were performed using the Proc Freq pro-
cedureh on the dependent variables (proportion of successes) for
microbiologic cure as the primary parameter, and clinical out-
come as the secondary parameter. The lower bound 1-sided 95%
confidence interval was calculated for the success rate difference
between group 1 and group 2, and was compared with 20%
margin of difference to determine noninferiority.
Body weight, sex, and the results of urinalysis on day 0 were
compared between groups. For continuous data, an analysis of
variance method was used that included treatment group, sex,
the interaction between treatment group and sex, and, where
applicable, a baseline covariate. For categorical data, Fisher’s
exact test was used.
Statistical analysis was performed using a statistical analysis
software packageg and an alpha level of 0.05 was used for statis-
tical significance. Data were expressed as means ± standard devi-
ations if normally distributed; otherwise, the median and range
were provided.
Results
Dogs
A total of 92 dogs were evaluated for entry into the
study on day 0 across all 5 study sites. Twenty-four
dogs ultimately were excluded. Nine dogs were
excluded because growth on urine culture was
<103 CFU/mL (n = 7), or growth on urine culture was
a nontargeted pathogen (n = 2). An additional 15 dogs
were excluded after enrollment because either the
organism grown on day 10 or day 21 was not the same
organism as day 0 (n = 2), owner noncompliance was
identified (n = 5), a concurrent disorder that may have
predisposed the dog to a UTI was documented
(n = 4), the incorrect dosage of medication was pre-
scribed (n = 2), the dog was removed from trial
because of an owner-perceived adverse event (n = 1),
or a medication was administered that was not allowed
according to the study protocol (n = 1).
Of the 68 remaining dogs included in the statistical
analysis, 35 (51.4%) were allocated to group 1 and 33
(48.5%) were allocated to group 2. Group 1 was com-
prised of 30 females and 5 males and group 2 was
comprised of 27 females and 6 males. There was no
difference in sex distribution between the 2 groups
(P = .75). All dogs in both groups were spayed or neu-
tered. Group 1 was comprised of 6 Labrador Retriev-
ers, 3 Boxers, 3 mixed breed dogs, 3 Siberian Huskies,
2 Golden Retrievers, 2 Dachshunds, and 1 each of var-
ious other breeds. Group 2 consisted of 6 mixed breed
dogs, 5 Labrador Retrievers, 3 Dachshunds, 3 Pugs, 2
Golden Retrievers, and 1 each of various other breeds.
The median body weight for group 1 dogs was 25.4 kg
(range, 5.0–48.8 kg) and for group 2 dogs was 19.0 kg
(range, 5.1–50.0 kg) (P = .42). The median age for
group 1 and group 2 dogs was 7.4 and 9.4 years,
respectively (P = .42).
No differences in clinical signs were noted between
the groups (Table 1). Ten dogs from group 1 and 8 dogs
from group 2 had all 3 LUTS. Bladder pain was identi-
fied in 6 dogs from group 1 and 7 dogs from group 2.
The mean urine specific gravity of group 1 and
group 2 dogs was 1.028 ± 0.012 (range, 1.005–1.050)
and 1.026 ± 0.013 (range, 1.002–1.052), respectively.
There was no difference in urine specific gravity
between the 2 groups (P = .92). The median urine pH
of group 1 and group 2 dogs was 7.5 (range, 5.0–9.0)
and 7.0 ± 1.1 (range, 5.0–8.5), respectively. There was
no difference in urine pH between groups (P = .72).
The most common pathogen isolated from both
groups was E. coli (Fig 1). Among group 1 dogs, urine
culture yielded  103 CFU/mL of a single pathogen in
33/35 (94.3%) dogs. In 1 dog, both E. coli and a
Staphylococcus spp. were isolated and in another, both
a Proteus spp. and Enterococcus spp. were isolated.
Among group 2 dogs, urine culture yielded
 103 CFU/mL of a single pathogen in 28/33 (84.8%)
dogs. From 5 dogs, significant growth occurred for 2
bacterial species. These were Staphylococcus spp., and
Table 1. Number and percentage of dogs with lower
urinary tract signs as reported by owners on day 0.
Group 1 dogs were treated with enrofloxacin for
3 days and group 2 dogs were treated with clavulanic
acid-amoxicillin for 14 days.
Clinical Sign
Group 1
(n = 35)
Group 2
(n = 33) P Value
Pollakiuria 33 (94.3) 33 (100) .5
Stranguria 21 (60.0) 19 (57.6) 1.0
Macroscopic hematuria 16 (45.7) 14 (42.4) .8
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Fig 1. All uropathogens cultured from all dogs at day 0. Group
1 dogs were treated with enrofloxacin for 3 days and group 2
dogs were treated with clavulanic acid-amoxicillin for 14 days.
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a Streptococcus spp., E. coli and a Proteus spp., a
Streptococcus spp. and a Citrobacter spp., a Proteus
spp. and Staphylococcus spp., and S. intermedius and
Staphylococcus felis.
Treatment Efficacy
Only 32 dogs in group 2 were included in the statis-
tical analysis of microbiologic cure because 1 dog was
withdrawn by the owner on day 7 because of persistent
LUTS, and follow-up urine culture could not be per-
formed. This dog was considered a clinical failure in
the analysis of clinical cure (see below). The microbio-
logic cure rate for dogs in group 1 and group 2 was
27/35 (77.1%) and 26/32 (81.2%), respectively. The
lowest end of the 95% confidence interval for this dif-
ference was 20.0%, which is equal to the 20% mar-
gin of difference and indicated noninferiority of the
group 1 treatment compared with that for group 2.
Of the 35 group 1 dogs, 8 (22.9%) had  103 CFU/
mL bacteria present on urine culture on day 10. Three
of these 8 dogs were males. E. coli was isolated ini-
tially and on day 10 from 5 dogs, and in 3 of those 5
dogs a second organism was present (2 had a Strepto-
coccus spp. and 1 an Enterobacter spp. infection). One
dog each had persistent positive cultures for a Staphy-
lococcus spp., Enterobacteriaceae spp., and an Entero-
coccus spp. Less than 103 CFU/mL of bacteria were
isolated from 2 additional dogs. These dogs were not
considered treatment failures according to the study
definition. On day 21, 1 of these 2 dogs had a negative
culture, and Enterococcus spp. was persistently isolated
from the urine of the second dog. Two of the dogs
that were treatment failures on day 10 (1 dog with an
E. coli and 1 with a Enterobacteriaceae spp.) subse-
quently were withdrawn from the study and no follow-
up cultures were obtained from these dogs on day 21.
Only 1 of these 2 dogs had LUTS. Furthermore, an
additional dog was withdrawn after day 10 because of
persistent LUTS. All of the remaining dogs completed
the study. The microbiologic cure rate on day 21 for
dogs in group 1 was 22/32 (68.8%).
Of the 32 group 2 dogs that were included in the
statistical analysis, 6 (18.8%) had positive urine cul-
tures on day 21. One of these dogs was male. E. coli
was isolated initially and at day 21 from 4 dogs, and 1
dog each had persistent positive cultures for a Proteus
spp. and Staphylococcus spp. One of the dogs with a
positive culture on day 21 had pollakiuria. No other
dogs with positive cultures had LUTS.
The clinical cure rate for group 1 and group 2 was
31/35 (88.6%) and 29/33 (87.9%), respectively. The
lowest end of the 95% confidence interval for this differ-
ence was 12.18%, which was higher than the 20%
margin of difference and indicated noninferiority.
Of all the group 1 dogs, 4/35 (11.4%) had LUTS on
day 10. All 4 dogs had pollakiuria and 1 of the 4 dogs
also had hematuria. Only 1 of the 4 dogs in group 1
with clinical signs on day 10 also had a positive urine
culture. The dog with pollakiuria and hematuria had a
negative urine culture at day 10, but, as mentioned,
was withdrawn from the study and no follow-up cul-
ture was obtained on day 21. At day 21, the clinical
cure rate for dogs in group 1 was 28/32 (87.5%).
Of all the group 2 dogs, 3/32 (9.4%) had LUTS on
day 21. One dog had stranguria, 1 had pollakiuria,
and 1 had stranguria, pollakiuria, and pain on bladder
palpation. Only the dog with pollakiuria alone had a
positive aerobic bacterial urine culture. One additional
dog in group 2 also was considered a clinical failure
because LUTS recurred and the dog returned for an
unscheduled recheck on day 7. Aerobic bacterial urine
culture was negative at that time.
Susceptibility Test Results
Of the group 1 dogs, 3/35 (8.6%) had positive
cultures on day 0 for organisms that were resistant to
enrofloxacin, and 1 additional dog had a positive
culture for an organism with intermediate susceptibility
to enrofloxacin. One of these 4 dogs had a positive cul-
ture for E. coli, and on day 10, this dog had a positive
culture for an E. coli as well as a Streptococcus spp.
and was considered a microbiologic failure. On day
21, aerobic bacterial urine culture for this dog was
negative despite no additional treatment. The 2nd dog
had a positive culture for a Streptococcus spp. on day
0, but on day 10, <103 CFU/mL of a Staphylococcus spp.
were isolated, so this dog was not considered a mi-
crobiologic failure. This dog also had a negative bacte-
rial urine culture on day 21. The 3rd dog had a
positive culture for E. coli on day 0, and on day 10,
 103 CFU/mL of an Enterobacteriaceae were iso-
lated. This was 1 of the 2 dogs withdrawn from the
study because of persistent positive culture. The 4th
dog had a positive culture for an Enterococcus spp. on
day 0 with intermediate susceptibility to enrofloxacin.
An Enterococcus spp. again was isolated ( 103 CFU/
mL) on days 10 and 21 with intermediate susceptibility
to enrofloxacin. Clinical cures occurred in all 4 of the
dogs. All of the other pathogens isolated from dogs in
group 1 on day 10 were susceptible to enrofloxacin.
When evaluating MIC values for amoxicillin-clavulanic
acid for group 1 dogs, only 1 dog had a uropathogen
(Pseudomonas spp.) that was resistant to amoxicillin-
clavulanic acid; this Pseudomonas spp. was susceptible
to enrofloxacin.
Of the group 2 dogs, 2/33 (6.1%) had positive
cultures for organisms on day 0 that were resistant to
amoxicillin-clavulanic acid. One of the dogs had a
positive culture for both a resistant E. coli and a sus-
ceptible Proteus spp. On day 21, <103 CFU/mL of an
unidentified bacteria was isolated from this dog, which
was considered a microbiologic cure. Clinical cure also
occurred in this dog. The other dog was positive for a
Staphylococcus spp. on day 0, but had a negative
culture on day 10 and day 21 and was free of LUTS.
All of the bacteria isolated from dogs on day 21 were
susceptible to amoxicillin-clavulanic acid. When evalu-
ating enrofloxacin MIC results for group 2 dogs, 2
dogs had pathogens resistant to enrofloxacin, and 1
had a pathogen with intermediate susceptibility; all 3
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isolates were Streptococcus spp. In all 3 dogs, the
pathogens were susceptible to amoxicillin-clavulanic
acid.
Adverse Events
For group 1 dogs, owners of 15 dogs reported a
total of 22 adverse events. In 4 dogs, the owners
reported adverse events on multiple days. Based on the
history, the attending clinician decided if the adverse
event was related to the antimicrobial administration.
The assessment was subjective because diagnostics and
serum drug concentrations were not obtained for these
dogs. The clinicians deemed 9 of the 22 events to be
unrelated to administration of the drug and included
such clinical signs as lethargy (n = 3), and 1 report
each of inappropriate urination, agitation, constipa-
tion, diarrhea, abdominal pain, and a small follicular
cyst that ruptured on the dog’s dorsum. Eleven events
were thought to be possibly (n = 8) or probably
(n = 3) related to administration of the enrofloxacin
and included vomiting (n = 3), lethargy (n = 3), diar-
rhea (n = 2), anorexia (n = 1), inappetence (n = 1),
and hypersalivation after drug administration (n = 1).
In 1 dog with lethargy and inappetence, the attending
clinician could not determine if the events were related
to administration of the antimicrobial because it
remained unclear if the dog had these clinical signs
before the study. Another dog that was treated with
enrofloxacin was removed from the study on day 2 as
a consequence of vomiting that occurred 1 and 3 hours
after administration of the antimicrobial drug. The
dog also was lethargic and inappetent, but responded
well to supportive care.
For the group 2 dogs, owners of 14 dogs reported a
total of 21 adverse events. In 2 dogs, the owners
reported adverse events on multiple days. Ten of the
21 events were thought to be unrelated to administra-
tion of the amoxicillin-clavulanic acid and included
anxiety (n = 3), polyphagia (n = 2), urinary inconti-
nence (n = 2), inappropriate urination (n = 1), poly-
dipsia (n = 1), and an epidermal inclusion cyst (n = 1).
Ten events were thought to be possibly (n = 8) or
probably (n = 2) related to the administration of the
antimicrobial and included a decreased appetite
(n = 5), vomiting (n = 3), diarrhea (n = 1), and consti-
pation (n = 1). In 1 case, the attending clinician could
not determine if the event (vomiting) was related to
administration of the antimicrobial because the owner
reported the clinical sign >5 days after it had occurred.
Discussion
In this study, we demonstrated that an HDSD enro-
floxacin protocol was not inferior to a 14-day antibiotic
treatment regimen using amoxicillin-clavulanic acid.
The latter is commonly used in clinical practice for
treatment of uncomplicated UTI in dogs.4 A total of
77.1% of dogs that received HDSD enrofloxacin had
negative urine cultures 7 days after completing antimi-
crobial treatment compared with 81.2% of dogs receiv-
ing the amoxicillin-clavulanic acid protocol. The HDSD
enrofloxacin protocol also was not inferior to amoxicil-
lin-clavulanic acid with regard to clinical cure rates.
We chose to study enrofloxacin and amoxicillin-
clavulanic acid because both drugs are used frequently
in clinical practice, are excreted in the urine, and have
good activity against many common urinary pathogens,
including those isolated in this study.25 Trimethoprim-
sulfamethoxazole also is recommended for treatment of
UTI in dogs,6,26 and its use is reported frequently in the
human literature.15 However, trimethoprim-sulfameth-
oxazole can cause hypersensitivity reactions in dogs,
including keratoconjunctivitis sicca.27 A number of
studies in humans have evaluated the efficacy of fluor-
oquinolones for treatment of uncomplicated UTI in
women.15,16 We chose to study 1 of the more commonly
used fluoroquinolones, enrofloxacin, which is labeled
for veterinary use. A higher dose of enrofloxacin was
prescribed because HDSD fluoroquinolone protocols in
human medicine were reported in some studies to have
slightly higher cure rates than low dose protocols.14
Our study only examined dogs diagnosed with
uncomplicated UTI, but the pathogens isolated were
similar to those previously reported for dogs with
UTI, some of which were recurrent or relapsing
infections.13,28–30 E. coli, Proteus spp., and Staphylo-
coccus spp. accounted for the majority of our isolates.
In contrast to other studies, we did not isolate Klebsi-
ella spp. from any of the dogs in our study. However,
we would expect either drug to have good activity
against most Klebsiella spp.25 As has been reported by
others,31 only a single bacterial species was isolated
from most dogs in our study.
Group 2 dogs had more gram positive uropathogens
cultured and no dog in group 2 had a Pseudomonas
spp. isolated. This study was randomized, and,
although a difference in the distribution of gram posi-
tive and gram negative pathogens existed between
groups (Fig 1), no difference in the prevalence of
E. coli was found between groups, which is the most
common uropathogen reported in dogs. Clinical and
microbiologic outcomes for dogs that had growth of
only E. coli (18 dogs in group 1 and 15 dogs in group
2) were not different, although the limited sample size
did not allow us to test for noninferiority (data not
shown). We designed our study as a clinical field trial
and chose to evaluate data for all pathogens because
evidence for differing treatment outcomes for different
pathogens is lacking and other variables, such as the
possession of virulence factors by different isolates of
the same bacterial species also may have the potential
to influence outcome.
For those dogs classified as a microbiologic failure,
we were unable to definitively identify relapse because
molecular investigations of the pathogens using pulse
field gel electrophoresis would be needed32 and this
testing was beyond the scope of this study. Even sus-
ceptibility patterns do not reliably distinguish between
relapsing or persisting infections and reinfections,
because antibiotic resistance patterns do not reflect the
genetic composition of the whole chromosome.33
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Both groups of dogs in this study contained a high
percentage of female dogs, which is similar to previous
studies of UTI in dogs.13,34 The microbiologic and clin-
ical cure rate for both groups was similar to short-term
cure rates reported for women with uncomplicated UTI
when given ciprofloxacin administered as a 250 or
750 mg single dose,35 which resulted in microbiologic
cure rates of 81.1 and 82.6%, respectively, and clinical
cure rates of 89 and 92%, respectively. However, an
absence of clinical signs did not imply negative culture
results in our study, and likewise, the presence of clini-
cal signs did not predict a positive culture after antimi-
crobial treatment was instituted. It appears that even in
dogs suspected to have uncomplicated UTI, urine
culture after antimicrobial treatment may be indicated
to be certain that bacteria have been eradicated.
Few studies have evaluated the efficacy of any dos-
ing regimen of antimicrobial treatment for UTI in
dogs. No studies of short duration oral antimicrobial
protocols for treatment of naturally occurring canine
UTI have been published. One-day and 3-day duration
treatment protocols were evaluated in an induced
E. coli canine cystitis model using either injectable
amikacin or oral trimethoprim-sulfadiazine.36 One-day
treatment with either of these drugs was not effective
in effecting bacteriological cure after treatment was
stopped. The 3-day treatment protocol using trimetho-
prim-sulfadiazine resulted in bacteriologically sterile
urine 14 days after treatment in 4 of 4 female dogs,
but in none of 4 male dogs. Cefovecin has been evalu-
ated for the treatment of uncomplicated UTI in dogs
when given as a single subcutaneous injection of 8 mg/
kg of body weight.30 Although this treatment was
reported to be effective, it is difficult to compare the
bacteriological results in this study to those in our
study because different time points and methods of
urine collection were used, as well as different defini-
tions for microbiologic or clinical cure. Furthermore,
cefovecin is not currently approved for the treatment
of UTI in dogs in the United States.
In human medicine, short-duration antimicrobial
protocols increase compliance, and result in lower costs
of treatment.19 In our study, owners were required to
keep a log of the drugs administered and compliance
was good in both groups we evaluated, although partic-
ipation in a study may have increased owner compli-
ance. Further studies would be required to determine if
owners who use short-duration protocols are more
inclined to administer all medications prescribed.
In our study, 91.4% of the isolates from dogs in
group 1 were susceptible to enrofloxacin and 93.9% of
the isolates from dogs in group 2 were susceptible to
amoxicillin-clavulanic acid. The microbiologic and
clinical cure rate in our study was lower than that
predicted by the organisms’ susceptibility for dogs
receiving either of the drug regimens used in this
study. When evaluating all dogs with persistent posi-
tive cultures, none had pathogens resistant to the anti-
microbial originally prescribed. The reasons for these
differences remain unclear. Although all dogs were
screened carefully for underlying diseases that could
result in complicated UTI, not all dogs had bladder
imaging studies performed and it is possible some dogs
with more complicated infections could have been
included in the study. Studies that investigate the resis-
tance patterns of urine bacterial isolates from dogs for
which the doses of the drugs administered and owner
compliance are evaluated also are warranted.
All potential adverse events were reported by own-
ers, but it was up to the attending to clinician to
decide if the event was associated with the antimicro-
bial administered. Adverse events were minimal and
only 1 dog that received HDSD enrofloxacin was
removed from the study because of gastrointestinal
signs. One dog in group 2 had persistent inappetence
during treatment, but remained in the study. All other
owners felt adverse effects encountered with either
antimicrobial protocol were not severe enough to
warrant removal from the study.
In summary, an HDSD enrofloxacin protocol was
not inferior when compared with a standard anti-
microbial regimen using amoxicillin-clavulanic acid for
uncomplicated UTI in dogs. The drug regimen was
well tolerated by most dogs and can be considered as
an alternative for treating uncomplicated UTIs in
dogs. Because antimicrobial resistance of canine uro-
pathogens to fluoroquinolones has been reported,37,38
further research is warranted to determine what impact
this protocol will have on the selection for antimicro-
bial-resistant bacteria. Additional research also should
be undertaken to determine if a shortened protocol
will positively impact owner compliance. Subsequent
studies can help develop guidelines for antimicrobial
dosing protocols for uncomplicated UTI.
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